We are live on ! Find out more
DAWN

Day One Biopharmaceuticals
DAWN

Delisted

DAWN was delisted on the 22nd of April, 2026.

Back to rankings

184 hedge funds and large institutions have $747M invested in Day One Biopharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 69 increasing their positions, 46 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

95% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 21

50% more repeat investments, than reductions

Existing positions increased: 69 | Existing positions reduced: 46

12% more funds holding

Funds holding: 164 → 184 (+20)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% less ownership

Funds ownership: 92.95% → 92.94% (-0%)

30% less call options, than puts

Call options by funds: $1.23M | Put options by funds: $1.76M

37% less capital invested

Capital invested by funds: $1.19B → $747M (-$441M)

Holders
184
Holders Change
+20
Holders Change %
+12.2%
% of All Funds
2.47%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
41
Increased
69
Reduced
46
Closed
21
Calls
$1.23M
Puts
$1.76M
Net Calls
-$533K
Net Calls Change
+$742K

Top Buyers

Rank Fund Capital Flow
1
PCH
Polar Capital Holdings
United Kingdom
+$23.3M
2
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$16.7M
3
VPC
Vestal Point Capital
New York
+$12.5M
4
Millennium Management
Millennium Management
New York
+$12.2M
5
Goldman Sachs
Goldman Sachs
New York
+$11.8M

Top Sellers

Rank Fund Capital Flow
1
FFM
Fairmount Funds Management
Pennsylvania
-$39.3M
2
TCM
TimesSquare Capital Management
New York
-$21.7M
3
B
Braidwell
Connecticut
-$14.4M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$13.8M
5
FTM
First Turn Management
California
-$12M
Name Holding Trade Value Shares
Change 		Change in
Stake
EC
26
EcoR1 Capital
California
$6.84M – – –
DCM
27
DAFNA Capital Management
California
$5.8M – – –
Morgan Stanley
28
Morgan Stanley
New York
$5.63M -$4M -370,853 -34%
AQR Capital Management
29
AQR Capital Management
Connecticut
$4.91M +$5.71M +530,429 +601%
Northern Trust
30
Northern Trust
Illinois
$4.25M -$119K -11,053 -2%
Charles Schwab
31
Charles Schwab
California
$4.19M -$79.2K -7,353 -1%
AG
32
Algert Global
California
$2.94M +$4M +371,380 New
SCM
33
Stonepine Capital Management
Oregon
$2.77M +$1.23M +113,820 +48%
Renaissance Technologies
34
Renaissance Technologies
New York
$2.76M +$1.13M +104,700 +43%
SFM
35
Sphera Funds Management
Israel
$2.66M – – –
Deutsche Bank
36
Deutsche Bank
Germany
$2.65M -$263K -24,398 -7%
KCM
37
Kennedy Capital Management
Missouri
$2.6M +$1.44M +133,779 +69%
SFI
38
Susquehanna Fundamental Investments
Pennsylvania
$2.56M +$3.48M +322,875 New
Qube Research & Technologies (QRT)
39
Qube Research & Technologies (QRT)
United Kingdom
$2.23M +$1.04M +96,128 +52%
Fisher Asset Management
40
Fisher Asset Management
Washington
$2.18M +$2M +186,075 +209%
PL
41
Parkwood LLC
Ohio
$2.18M – – –
Bank of New York Mellon
42
Bank of New York Mellon
New York
$1.97M +$38.3K +3,551 +1%
WP
43
Woodline Partners
California
$1.69M -$6.31M -585,771 -73%
TI
44
Trexquant Investment
Connecticut
$1.62M +$1.26M +116,810 +133%
Royal Bank of Canada
45
Royal Bank of Canada
Ontario, Canada
$1.47M +$576K +53,459 +40%
Norges Bank
46
Norges Bank
Norway
$1.34M – – –
Citigroup
47
Citigroup
New York
$1.31M +$90.9K +8,442 +5%
BNP Paribas Financial Markets
48
BNP Paribas Financial Markets
France
$1.28M +$1.35M +125,319 +342%
Barclays
49
Barclays
United Kingdom
$1.23M +$148K +13,757 +10%
N
50
Nuveen
North Carolina
$1.11M -$17.7K -1,640 -1%
1
2
3 4 5

DAWN Hedge Fund Activity: Q1 2025 in Review

184 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2025, worth a combined $747M — down 37% from $1.19B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new DAWN positions and 21 closed out — a net gain of 20 holders — while 69 added to existing stakes and 46 trimmed.

The largest buyer was Polar Capital Holdings, adding an estimated $23.3M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $39.3M sold.

  • 184 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2025, up from 164 in Q4 2024.
  • Funds reported $747M of Day One Biopharmaceuticals stock for Q1 2025, down 37% quarter-over-quarter.
  • 41 funds opened new Day One Biopharmaceuticals positions in Q1 2025 and 21 closed out, a net change of +20 holders.
  • The largest Day One Biopharmaceuticals buyer in Q1 2025 was Polar Capital Holdings, an estimated $23.3M added.
  • The largest Day One Biopharmaceuticals seller in Q1 2025 was Fairmount Funds Management, an estimated $39.3M sold.

Based on aggregated 13F filings for Q1 2025.